for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hangzhou Tian-Mu-Shan Pharm. Enterp. Co

600671.SS

Latest Trade

9.08CNY

Change

0.06(+0.67%)

Volume

345,798

Today's Range

8.94

 - 

9.18

52 Week Range

5.97

 - 

12.82

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
9.02
Open
8.94
Volume
345,798
3M AVG Volume
10.72
Today's High
9.18
Today's Low
8.94
52 Week High
12.82
52 Week Low
5.97
Shares Out (MIL)
121.78
Market Cap (MIL)
1,098.45
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2020 Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Earnings Release

Latest Developments

更多

Great Wall Belt & Road Notes SSE On 28 Dec Publicly Censured A Director Of Hangzhou TianMuShan

Hangzhou Tianmushan Pharma's 25 Mln Shares Owned By Controlling Shareholder To Be Auctioned

Hangzhou Tianmushan Pharmaceutical Probed For Suspected Violation Of Information Disclosure

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hangzhou Tian-Mu-Shan Pharm. Enterp. Co

Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.

Industry

Biotechnology & Drugs

Contact Info

Building 3

Xixile Valley, No.738, Wener West Road

HANGZHOU, ZHJ

311300

China

+86.571.63722229

Executive Leadership

Feifan Zhao

Chairman of the Board, Acting Chief Financial Officer

Yulin Li

Vice Chairman of the Board

Yining Xu

Vice Chairman of the Board

Chengquan Yang

Vice Chairman of the Board

Zuyue Li

General Manager

Key Stats

Price To Earnings (TTM)
24.79
Price To Sales (TTM)
4.61
Price To Book (MRQ)
10.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
111.49
LT Debt To Equity (MRQ)
30.25
Return on Investment (TTM)
15.36
Return on Equity (TTM)
8.15

Latest News

Latest News

沪综指收低月线跌1.6% 香港恒生指数收跌1.3%

中国股市周三收盘下跌,美国总统特朗普对中国发出新威胁,房地产开发商类股下挫,因政府对房地产行业的支持性政策基调减弱。

(修正)中国股市收盘下跌 受贸易和增长担忧拖累

中国股市周三量缩收低,延续上日的小跌走势,投资者仍担心增长放缓以及美中贸易冲突的影响,并等待更多政府将推出支持举措的信号。

中国股市收低 市场对经济前景的看法分歧

中国股市连续三日上扬后周二收低,投资者担心中国经济增长放缓,以及中美贸易战的影响,尽管最新数据凸显出政府加大支出的努力见效。

沪综指收涨逾1%创逾一年来高位 受经济复苏及贸易谈判进展激励

沪深300指数<.CSI300>收高1.3%,至4,022.16点,沪综指<.SSEC>收高1.2%,至3,216.30点,双双收于2018年3月底以来最高位。

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up